News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

India Revokes GlaxoSmithKline (GSK) Cancer Drug Patent in Latest Big Pharma Blow



8/2/2013 7:20:04 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

India has revoked a patent granted to GlaxoSmithKline Plc for breast cancer drug Tykerb, a decision that follows a landmark India court ruling disallowing patents for incremental innovations that was a blow to global pharmaceutical firms. However, India's Intellectual Property Appellate Board (IPAB) upheld a patent granted on the original compound, or active pharmaceutical ingredient, lapatinib, citing innovative merit. As a result, a GSK spokesman said its medicine would remain subject to patent protection until 2019.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at India Times
Read at News Release
Read at Zee News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES